Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels-Reference-Cited by-同舟云学术

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

Published:2009-02 Issue:2 Volume:33 Page:271-275
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Forrest Donna L.,Trainor Shannon,Brinkman Ryan R.,Barnett Michael J.,Hogge Donna E.,Nevill Thomas J.,Shepherd John D.,Nantel Stephen H.,Toze Cynthia L.,Sutherland Heather J.,Song Kevin W.,Lavoie Julye C.,Power Maryse M.,Abou-Mourad Yasser,Smith Clayton A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference11 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;New England Journal of Medicine,2006

2. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance;Hochhaus;Leukemia,2004

3. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients;Peng;Journal of Clinical Oncology,2004

4. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia;Picard;Blood,2007

5. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study;Larson;Blood,2008

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling;ACS OMEGA;2023

2. Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling;ACS Omega;2023-04-03

3. Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic‐phase chronic myeloid leukemia;Cancer;2022-10

4. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success;American Journal of Hematology;2022-04-12

5. Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens;British Journal of Clinical Pharmacology;2021-10-15